Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Endocrine 3

Conditions

Breast Neoplasms 987Neoplasms 796Carcinoma, Non-Small-Cell Lung 763Prostatic Neoplasms 588Colorectal Neoplasms 484Lung Neoplasms 468Neoplasm Metastasis 413Multiple Myeloma 382Leukemia, Myeloid, Acute 377Ovarian Neoplasms 316Pancreatic Neoplasms 297Melanoma 278Squamous Cell Carcinoma of Head and Neck 258Recurrence 244Carcinoma, Hepatocellular 240Brain Neoplasms 226Glioblastoma 217Triple Negative Breast Neoplasms 204Carcinoma, Renal Cell 200Head and Neck Neoplasms 198Lymphoma 193Stomach Neoplasms 190Precursor Cell Lymphoblastic Leukemia-Lymphoma 189Sarcoma 172Glioma 171Uterine Cervical Neoplasms 169Lymphoma, Non-Hodgkin 169Endometrial Neoplasms 169Lymphoma, Large B-Cell, Diffuse 166Urinary Bladder Neoplasms 160

Interventions

relacorilant 1Deamino Arginine Vasopressin 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pituitary ACTH Hypersecretion × 90 days × Clear all
NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT04569591 2026-04-09

DDAVP for Pituitary Adenoma

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
22 enrolled
Endocrine

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT07460232 2026-03-10

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

Mayo Clinic

Phase EARLY_PHASE1 Not yet recruiting
50 enrolled
Endocrine

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡